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Abstract
Objectives. To evaluate the effect of secukinumab, a fully human anti-interleukin-17A monoclonal anti-
body, on efficacy, imaging outcomes, and safety through 4 years (208 weeks) in patients with ankylosing
spondylitis.
Methods. Patients opting to enrol had completed 2 years’ treatment in the MEASURE 1 core study with
subcutaneous secukinumab 150 or 75 mg every 4 weeks (q4Wk), following intravenous loading to Week
(Wk) 4, or placebo treatment to Wk16/24. Up-titration from secukinumab 75150 mg q4Wk was permitted
following a protocol amendment. Efficacy is reported for patients originally randomized to secukinumab.
Radiographic changes were assessed using the modified Stoke Ankylosing Spondylitis Spinal Score
(mSASSS) and changes in MRI measures of inflammation using the Berlin scoring method. Safety and
tolerability were evaluated.
Results. Among 274 extension study participants, 89.7% (78/87) and 93.0% (93/100) originally rando-
mized to secukinumab 150 and 75 mg, respectively, completed 208Wk. Through Wk208, Assessment of
Spondyloarthritis International Society 20/40 (observed) were 79.7%/60.8% (150 mg), 71.0%/43.5%
(75 mg) and 80.0%/76% (up-titrators; n= 25). Mean (S.D.) changes in mSASSS were 1.2 (3.91) (150 mg),
1.8 (4.32) (75 mg) and 1.6 (5.67) (up-titrators). No radiographic progression (mSASSS change from
Baseline<2) was observed in 79% of patients receiving either secukinumab dose. Exposure-adjusted
incidence rates per 100 patient-years were: serious infections (1.0), Candida infections (0.4), Crohn’s
disease (0.6), ulcerative colitis (0.2), and malignant/unspecified tumours (0.5), with no new safety signals.
Conclusion. Through 4 years, secukinumab provided sustained efficacy on signs and symptoms, and MRI
outcomes, a low rate of radiographic progression and a consistent safety profile.
Trial registration: NCT01863732.
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Rheumatology key messages
. First study reporting longer-term effect of secukinumab on radiographic structural progression in ankylosing spondylitis.
. Secukinumab 150 mg demonstrated low radiographic progression through 4 years.
. Secukinumab 150 mg demonstrated sustained efficacy with a consistent and favourable safety profile through 4 years.
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Introduction
AS is a chronic inflammatory disease that primarily affects
the axial skeleton, manifesting as inflammatory back pain
and stiffness [1]. AS can be associated with progressive
irreversible structural damage, which occurs as a result of
syndesmophyte formation and ankylosis of the vertebral
column [2]. Several risk factors, including smoking,
gender, elevated levels of high-sensitivity CRP (hsCRP),
and radiographic damage at baseline positively influence
the pathologic formation of new bone in the spinal joints of
patients with AS [35]. Patients with AS experience
reduced physical function and quality of life because of
these chronic structural changes [6, 7]. The primary goals
of AS treatment include maintaining patients’ long-term
health-related quality of life and functional status through
the control of symptoms and inflammation, as well as the
prevention of progressive structural damage [8, 9].
Secukinumab, a fully human anti-interleukin IL-17A
monoclonal antibody, demonstrated sustained improve-
ments in the signs and symptoms of AS through 2 years
in two Phase 3 studies (MEASURE 1: NCT01358175 and
MEASURE 2: NCT01649375), and a low rate of structural
radiographic progression in MEASURE 1 [10, 11].
Furthermore, results of the ongoing 3-year extension
(NCT01863732) to the 2-year MEASURE 1 core trial (i.e.
5 years total) has provided longer-term data demonstrating
sustained efficacy through a total 3 years of treatment [12].
Here, we present an update on the efficacy and safety of
secukinumab from the open-label extension of the
MEASURE 1 trial through 4 years (208Wk) in patients with
AS, including the results of radiographic and MRI analyses.
Methods
Study design and participants
The study design and patient eligibility criteria of this 3-
year extension of the MEASURE 1 core trial have been
described previously (Supplementary Fig. S1, available
at Rheumatology online) [12, 13]. Briefly, subjects
518 years with AS fulfilling the modified New York
Criteria, and active disease as indicated by a BASDAI
score 54 [14], and a spinal pain score 54 cm (on a
010 cm scale) despite prior treatment with NSAIDs
were included. Subjects were anti-TNF naı¨ve or anti-TNF
IR (i.e. had experienced an inadequate response or
stopped treatment for safety/tolerability reasons).
Patients randomized to secukinumab received a 10 mg/
kg intravenous (IV) loading dose at baseline, Wk2 and
Wk4, and then subcutaneous injections of 150 mg
(IV!150 mg) or 75 mg (IV!75 mg) q4Wk from Wk8. The
same IV-to-subcutaneous schedule was administered for
subjects on placebo up to Wk16 (non-responders) or
Wk24 (responders), when subjects were switched to
secukinumab, as previously described [13]. Following a
protocol amendment, subjects on secukinumab 75 mg
not achieving sufficient therapeutic response could be
up titrated to 150 mg at investigators’ discretion.
Subjects completing the 2-year core trial were invited to
continue their treatment in the open-label 3-year exten-
sion, which was conducted in accordance with the prin-
ciples of the Declaration of Helsinki. All centres received
approval from independent ethics committees or institu-
tional review boards. Patients provided written informed
consent before starting the study-related procedures. The
names of independent ethics committees or institutional
review boards that approved the study and the associated
approval numbers are listed in Supplementary Table S6,
available at Rheumatology online.
Endpoints
Assessments of clinical efficacy and quality of life included
Assessment of Spondyloarthritis International Society
(ASAS) 20/40 response, ASAS5/6, Ankylosing
Spondylitis Disease Activity Score inactive disease,
BASDAI, BASMI, BASFI, short form-36 physical compo-
nent summary and ASAS partial remission.
Lateral radiographs of the cervical and lumbar spine
were assessed using the modified Stoke Ankylosing
Spondylitis Spinal Score (mSASSS, range 072, with
higher scores indicating greater structural damage) [15],
as previously described [10]. MRI of the SI joints and spine
was used to investigate the effect of secukinumab on ob-
jective signs of inflammation in a subset of anti-TNF-naı¨ve
subjects at selected study centres; MRIs were assessed
using the Berlin SI joint total oedema score and the Berlin
spine score (derived from ASspi-MRI-a results).
Radiographs and MRIs obtained at baseline and Wk104
were re-read for patients completing 208Wk of treatment.
All imaging data were evaluated by two experienced cen-
tral readers, blinded to treatment and visit, and mean
scores were analysed. The proportion of patients who
achieved MRI remission (Berlin spine score of 42) up to
Wk208 was investigated in a subset of anti-TNF-naı¨ve pa-
tients with baseline Berlin spine score of >2 and at least
one post-baseline Berlin spine score at Wk156 or 208 [10].
The safety and tolerability of secukinumab were evalu-
ated through Wk208 via assessment of treatment-emer-
gent adverse events (AEs) and serious AEs (SAEs).
Statistical analyses
Clinical efficacy analyses at Wk208 were reported as
observed for subjects originally randomized at baseline
to secukinumab 150 or 75 mg, with data for the 75 mg
group stratified by up-titration status.
Predefined hierarchical variables with secukinumab
150 mg were also analysed using multiple imputation to
account for missing data for binary efficacy variables, and
mixed-model for repeated measures for continuous vari-
ables. Visit and anti-TNF status (naı¨ve or IR) were included
in the mixed-model for repeated measures as fixed fac-
tors, weight and baseline score as covariates, and visit by
baseline score as an interaction term. Multiple imputation
or mixed-model for repeated measures were not done for
the 75 mg arm because the assumption of missing at
random was violated in subjects who up-titrated to secu-
kinumab 150 mg. For patients who discontinued treatment
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during Wk108156, the end of treatment visit (i.e. the final
assessment 4Wk after last study treatment) was con-
sidered as Wk156. For patients who discontinued during
Wk160208, the end of treatment visit was considered as
Wk208. Pre-specified analyses in anti-TNF naı¨ve and IR
subjects were reported as observed in the secukinumab
treatment groups to which subjects were originally
randomized.
Imaging data (radiographic/MRI) were reported as
observed at each time point assessed. In analyses of
the change in mSASSS between timepoints, the data cap-
ture window for Wk104 X-rays was extended from
31743 days to 31849 days to include 10 and 14 add-
itional patients in the secukinumab 150 and 75 mg
groups, respectively. Change from baseline in mSASSS
was stratified by baseline demographic and disease char-
acteristics including hsCRP, gender, presence of
syndesmophytes and smoking status. Proportion of non-
progressors (i.e. subjects achieving change in mSASSS
from baseline <2) was also reported.
Safety analyses were reported for all subjects receiving
51 dose of secukinumab at any time during the core trial
or extension, including those randomized at baseline to
secukinumab or placebo. Patients who up-titrated were
assessed according to the treatment received at the
time of the AE.
Results
Patients
Of the 274 subjects enrolled in this extension study,
89.7% (78/87) and 93.0% (93/100) originally assigned to
secukinumab 150 and 75 mg, respectively, completed
208Wk of treatment. Remaining subjects were re-rando-
mized from placebo to either secukinumab dose and were
included in safety but not efficacy analyses. 25 subjects
originally randomized to secukinumab 75 mg up-titrated to
150 mg at various timepoints from Wk168.
The majority of discontinuations with secukinumab
150 mg (7/9 [77.8%]) and 75 mg (3/7 [42.9%]) were attrib-
uted to subject/guardian decision (Supplementary Table
S1, available at Rheumatology online). Demographic and
baseline characteristics of the extension trial population
have been reported previously [12].
Clinical efficacy
ASAS20/40 response rates at Wk208 were similar to those
reported at Wk52 and Wk104 (Fig. 1A and B;
Supplementary Table S2, available at Rheumatology
online) [10, 12, 13]: 79.7%/60.8% (as observed) and
76.4%/58.0% (multiple imputation) with secukinumab
150 mg. As observed, ASAS20/40 responses with secuki-
numab 75 mg were 71.0%/43.5% for subjects who did not
up-titrate and 80.0%/76.0% for subjects who had a dose
increase to 150 mg (Table 1). Secukinumab 150 mg pro-
vided sustained efficacy across other clinical endpoints
including BASDAI, with consistent findings for observed
and imputed analyses (Fig. 1C; Supplementary Table S2,
available at Rheumatology online). Numerically improved
or comparable as observed responses were seen for most
endpoints in subjects who up-titrated from secukinumab
75150 mg (n= 25) vs those who did not up-titrate (n= 75)
(Table 1), except for ASAS partial remission and
Ankylosing Spondylitis Disease Activity Score inactive
disease.
Results for key efficacy endpoints were generally com-
parable across anti-TNF-naı¨ve and -IR subgroups, except
for ASAS40 and ASAS partial remission, which showed a
higher proportion of patients in the naı¨ve subgroup
(Supplementary Table S3, available at Rheumatology
online).
Radiographic outcomes
A total of 71 and 84 subjects in the secukinumab 150 and
75 mg groups, respectively, had X-rays at baseline and
Wk208, with 63.4% and 75.0% being male in the secuki-
numab 150 and 75 mg groups, respectively. Mean (S.D.)
mSASSS at baseline was 8.8 (16.23) and 10.7 (17.82) in
the secukinumab 150 and 75 mg groups, respectively
(Supplementary Table S4, available at Rheumatology
online).
No radiographic progression (mSASSS change from
baseline <2) was observed over 208Wk in 78.9%
(150 mg) and 78.6% (75 mg) of patients (Fig. 2). Mean
(S.D.) change in mSASSS from baseline to Wk208 was
numerically lower with secukinumab 150 vs 75 mg: 1.2
(3.91) with secukinumab 150 mg vs 1.8 (4.32) and 1.6
(5.67) with secukinumab 75 mg in subjects who did and
did not up-titrate, respectively. Numerically smaller
changes were also observed with secukinumab 150 vs
75 mg from baseline to Wk104 and Wk104 to Wk208
(Fig. 3). Changes in mSASSS were consistent for the 67
(150 mg) and 79 (75 mg) patients who had X-ray data
available at all three timepoints (Baseline, Wk104 and
Wk208; Supplementary Fig. S2, available at
Rheumatology online).
Mean mSASSS changes from baseline at Wk208 were
numerically greater in subjects with vs without baseline
syndesmophytes, in subjects with elevated (>5 mg/L) vs
normal (45 mg/L) baseline hsCRP, and in males vs fe-
males across both secukinumab doses, regardless of
up-titration. Compared with patients who had never
smoked, ever-smokers (ie previous/current smokers) had
numerically higher mean mSASSS changes in subjects
with secukinumab 75 mg, regardless of up-titration
(Table 2).
MRI
Reductions from baseline in the Berlin SI joint total
oedema and Berlin spine scores were seen across both
doses at Wk104 and 208, with numerically greater de-
creases in Berlin SI joint total oedema and Berlin spine
scores at Wk104 with secukinumab 150 vs 75 mg
(Supplementary Table S5, available at Rheumatology
online). Reduction in these scores was sustained through
Wk208, with the reduction from baseline in Berlin SI joint
total oedema score being numerically greater with secu-
kinumab 150 than 75 mg at Wk208. MRI remission was
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achieved in 33.3% (1/3) and 62.5% (5/8) of patients trea-
ted with secukinumab 150 mg and 75 mg, respectively, at
Wk208. However, given the small number of anti-TNF-
naı¨ve patients meeting the baseline analysis criteria (i.e.
Berlin spine score >2), generalizable conclusions regard-
ing MRI remission with secukinumab cannot be drawn.
Safety
Safety analyses of patients originally randomized to secu-
kinumab and placebo patients re-randomized to secuki-
numab at Wk16/24 were combined into ‘Any
secukinumab 150 mg’ and ‘Any secukinumab 75 mg’
groups. Across the entire treatment period (secukinumab
exposure [mean (S.D.)]: 1242.6 (524.05) days in ‘Any secu-
kinumab group’), the most common AEs with secukinu-
mab were viral upper respiratory infections (Table 3). SAE
incidence (95% CI) was 11.9% (8, 17.2) and 20.1% (14.7,
26.9) in the ‘Any secukinumab 150 and 75 mg groups’,
respectively. Discontinuations due to AEs were infrequent
and comparable between the two doses. There were two
deaths during the study, which have been reported previ-
ously [10, 12]. No suicides were reported. There was one
mild AE of latent tuberculosis infection and one SAE of
primary tuberculoma through Wk208 in patients treated
with secukinumab 75 mg (Table 3).
Exposure-adjusted incidence rates (EAIRs, per 100
subject-years) through Wk208 are presented in Table 3.
The 12 serious infections through Wk208 were reported
previously [10, 12]. Candida infections were reported in
five secukinumab-treated patients through Wk208, with
one new case in Wk156208 [10]. Through 208Wk, there
were seven Crohn’s disease cases; neither of the two
FIG. 1 (A) ASAS20, (B) ASAS40 responses and (C) mean change from baseline in BASDAI through Wk208
Data are presented for patients originally randomized to secukinumab IV-150 mg. ASAS 20/40 are reported as observed
and using multiple imputation. For BASDAI, mean change from baseline is reported as observed data and as least-square
mean change (MMRM analysis). ASAS: Assessment of Spondyloarthritis International Society; IV: intravenous; MMRM:
mixed model repeated measures; n: number of evaluable patients; N: total number of patients initially randomized to
secukinumab 150 mg at baseline; Obs: observed data; Wk: week.
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patients reporting Crohn’s disease in Wk156208 had a
history of inflammatory bowel disease. One case was a
non-SAE that resolved with treatment; the other, SAE, was
unresolved, resulting in treatment discontinuation. Two
patients reported ulcerative colitis through Wk208, one
of which was reported through Wk156 [12]. The second
non-SAE was moderate in severity and occurred in
Wk156208 in a patient without pre-existing history; the
unresolved case resulted in treatment discontinuation. Six
cases of malignant/unspecified tumours were reported
through Wk208, with one occurring in Wk156208 [10,
12]. Prior history of uveitis was reported in 17% (62/371)
of the MEASURE 1 study population at baseline [10].
Through Wk208, uveitis was reported by 21 secukinu-
mab-treated patients, of whom 12 had pre-existing history
and nine were de novo cases; no SAEs of uveitis were
reported during Wk156208. The seven adjudicated
major adverse cardiac events were reported previously
[10, 12].
Discussion
These results demonstrate the sustained efficacy of secu-
kinumab in both clinical and radiographic outcomes
through 4 years in the MEASURE 1 study, the first study
reporting the longer-term effect of secukinumab on radio-
graphic structural progression in AS; previous publica-
tions reported efficacy and radiographic outcomes from
the 2-year core study [10].
Clinical improvements were sustained across all end-
points through Wk208, with numerically greater improve-
ments with secukinumab 150 vs 75 mg. This is consistent
with the 3-year results [12], where decreased efficacy was
observed with 75 vs 150 mg (the licensed dose in AS),
particularly with higher-hurdle endpoints (e.g. ASAS par-
tial remission). These results represent the longest-term
efficacy results reported for an IL-17 inhibitor in AS and
are notable for demonstrating no evidence of decreasing
FIG. 3 Change in mSASSS between (A) Baseline to Wk104, (B) Wk104 to Wk208, (C) Baseline to Wk208
*Includes 23 patients (22 patients of whom had X-ray data at baseline, Wk104 and Wk208) whose dose was up-titrated
from secukinumab 75 mg to 150 mg at various timepoints starting at Wk168. mSASSS score ranges from 072; higher
scores indicate greater radiographic damage.  represents mean (s.d.) difference in mSASSS between timepoints.
Baseline and Wk104 X-rays were re-read with Wk208 X-rays to minimize longitudinal variability. BL: baseline; IV: intra-
venous; mSASSS: modified Stoke Ankylosing Spondylitis Spine Score; n: number of patients with assessments at both
timepoints; Wk: week.
FIG. 2 Cumulative probability plot for change from base-
line in the mSASSS through Wk208
*Includes 23 patients whose dose was up-titrated from
secukinumab 75 mg to 150 mg at various timepoints
starting at Wk168, in accordance with a protocol
amendment at the discretion of investigators. Data shown
as observed. mSASSS: modified Stoke Ankylosing
Spondylitis Spine Score; IV: intravenous; n: number of
patients with evaluable paired X-rays at Baseline and
Wk208; Wk: week.
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efficacy with long-term use in both observed and imputed
analyses, in contrast to the secondary treatment failure
reported with long-term use of anti-TNF agents [16, 17].
This finding with secukinumab, a fully human monoclonal
antibody, is consistent with the reported low rates of im-
munogenicity (rates of treatment-emergent anti-drug anti-
bodies typically <1%) [18].
Among subjects originally randomized to secukinumab
75 mg, numerically improved responses were observed on
most endpoints in those who up-titrated to secukinumab
150 mg vs those who did not up-titrate. These results
should be interpreted with caution due to the relatively
small number of subjects who up-titrated and the limited
observation window. As patients were allowed to up-ti-
trate at investigators’ discretion at any point after Wk156
following a protocol amendment, there was a wide distri-
bution of exposure time on secukinumab 150 mg (440
Wk), which may explain why a consistent pattern was
not seen across all endpoints (eg ASAS partial remission)
in up-titrated subjects. End-of-study results to be re-
ported at the conclusion of the 3-year extension trial
should confirm whether this trend continues in the setting
of longer-term up-titration of 12 years in all up-titrated
subjects. Whether treatment with higher doses of secuki-
numab (300 mg q4Wk) has an even stronger effect on
radiographic progression is unknown; a recent study
showed a trend towards better clinical effects in some
patients [19].
Sustained improvements were seen in anti-TNF-naı¨ve
and -IR subgroups, with similar improvements observed
across both subgroups in all endpoints, except for
ASAS40 and ASAS partial remission, where improve-
ments were greater in anti-TNF-naı¨ve subjects. The
results demonstrate that secukinumab is a suitable
longer-term AS treatment option for both biologic-naı¨ve
subjects as first-line biologic therapy and those who ex-
perience an inadequate response or intolerance to anti-
TNF agents.
This study represents the first long-term (4-year)
data from a controlled study of a biologic in AS to sug-
gest a dose-response effect for structural progression,
with a numerically lower mSASSS change from baseline
with secukinumab 150 vs 75 mg, regardless of up-
titration, through Wk208. In the GO-RAISE study,
which evaluated two doses of the anti-TNF golimumab
through 4 years, no benefit was observed with the
higher dose: mean (S.D.) change from baseline in
mSASSS with 50 vs 100 mg were 0.9 (2.7) vs 0.9 (3.9)
over 2 years, and 1.3 (4.1) vs 2.0 (5.6) over 4 years, re-
spectively [20].
TABLE 2 Mean mSASSS change from baseline to Wk208 in different subgroups of patients (observed data)
mSASSS, mean (S.D.)
Secukinumab
IV!150mg
Secukinumab
IV!75 mg
Not up-titrated
(N=75)
Up-titrated to secukinumab
150 mga (N=25)
Syndesmophytes at baseline
Yes (n= 32) No (n= 39) Yes (n= 32) No (n= 29) Yes (n= 11) No (n= 12)
Baseline 18.8 (19.63) 0.2 (0.71) 16.2 (17.12) 0.1 (0.30) 32.6 (24.18) 0.3 (0.62)
Change at Wk208
from baseline
2.1 (4.61) 0.5 (3.10) 3.1 (5.56) 0.2 (1.13) 3.3 (8.04) 0.0 (0.00)
Elevated hsCRPb at baseline
Yes (n= 48) No (n= 23) Yes (n= 37) No (n= 24) Yes (n= 17) No (n= 6)
Baseline 10.6 (17.75) 4.4 (10.91) 11.8 (16.72) 3.4 (9.15) 18.8 (25.80) 7.0 (10.84)
Change at Wk208
from baseline
1.8 (4.64) 0.2 (0.90) 2.3 (4.35) 0.9 (4.23) 2.8 (5.66)  1.8 (4.49)
Male
Yes (n= 45) No (n= 26) Yes (n= 43) No (n= 18) Yes (n= 20) No (n= 3)
Baseline 12.1 (18.75) 2.5 (6.48) 10.8 (16.82) 3.1 (4.76) 17.8 (24.24) 1.7 (1.53)
Change at Wk208
from baseline
1.5 (3.98) 0.8 (3.80) 2.3 (4.89) 0.6 (2.17) 1.8 (6.06) 0.0 (0.00)
Ever-smoker at baseline
Yes (n= 21) No (n= 50) Yes (n= 24) No (n= 37) Yes (n= 8) No (n= 15)
Baseline 8.7 (13.31) 8.6 (17.20) 14.1 (16.11) 4.9 (12.71) 7.3 (9.67) 20.2 (27.15)
Change at Wk208
from baseline
0.9 (1.94) 1.4 (4.49) 2.0 (4.32) 1.6 (4.38) 3.8 (6.86) 0.4 (4.78)
Data shown as mean (S.D.). mSASSS ranges from 0 to 72, with higher scores indicating greater radiographic damage.
aFollowing the approval of a protocol amendment, patients in the 75 mg group not achieving sufficient therapeutic response
could have their dose escalated to 150 mg at the discretion of the investigators; this led to 25 patients originally randomized to
secukinumab 75 mg being up-titrated to secukinumab 150 mg at various timepoints starting at Wk168. bElevated hsCRP:
>5 mg/L; normal hsCRP: 45 mg/L. hsCRP: high-sensitivity CRP; IV: intravenous; mSASSS: modified Stoke Ankylosing
Spondylitis Spine Score; n: number of patients with evaluable paired X-rays at baseline and Wk208; Wk: week.
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Results of the current study also demonstrate no radio-
graphic progression (change from baseline in mSASSS
<2) in almost 80% of secukinumab-treated patients
through Wk208; this finding is consistent with the
MEASURE 1 core study, in which 80% of secukinu-
mab-treated patients experienced no radiographic struc-
tural progression through 2 years (change in
mSASSS< smallest detectable change = 1.83) [10].
Results of the core and extension studies can’t be directly
compared as only 74% of core study participants enrolled
in the extension study. Additionally, baseline and Wk104
X-rays were re-read for patients completing 208Wk.
As expected, and consistent with the core study findings,
mean mSASSS changes through Wk208 were numerically
higher in patients with known risk factors for progression,
including baseline syndesmophytes, male gender and ele-
vated hsCRP [35, 10].
Prevention of progressive structural damage is a key ob-
jective of AS treatment [8, 9]. Previous studies have failed to
show a reduction in radiographic structural progression over
2 years in subjects treated with anti-TNF agents vs historical
control-matched subjects from an anti-TNF naı¨ve population
[2123], despite recent certolizumab data demonstrating
low mSASSS progression rates over 4 years and non-
TABLE 3 Safety and tolerability of secukinumab during the entire treatment period through Wk208
Variable
Any secukinumab
150mg (N=218)a
Any secukinumab
75mg (N=179)a
Any secukinumab
(N=360)
Total exposure to study treatment (days)b 1002.7 (617.93) 1278.0 (504.58) 1242.6 (524.05)
Number of patients with event, n (%)
Any AE 175 (80.3) 151 (84.4) 313 (86.9)
SAEc 36 (20.1) 26 (11.9) 62 (17.2)
Any AE leading to discontinuationd 19 (8.9) 13 (7.3)e 32 (8.9)
Death, n (%)f 0 (0.0) 2 (1.1) 2 (0.6)
Common AEs (seen in >5% of subjects on secukinumab), n (%)
Viral upper respiratory tract infection 46 (21.1) 36 (20.1) 80 (22.2)
Diarrhoea 29 (13.3) 25 (14.0) 52 (14.4)
Headache 25 (11.5) 26 (14.5) 51 (14.2)
Upper respiratory tract infection 19 (8.7) 29 (16.2) 48 (13.3)
Influenza 23 (10.6) 19 (10.6) 42 (11.7)
Pharyngitis 23 (10.6) 13 (7.3) 36 (10.0)
Dyslipidaemia 14 (6.4) 18 (10.1) 32 (8.9)
Arthralgia 17 (7.8) 16 (8.9) 32 (8.9
Back pain 19 (8.7) 12 (6.7) 31 (8.6)
Oropharyngeal pain 17 (7.8) 14 (7.8) 31 (8.6)
Cough 15 (6.9) 12 (6.7) 27 (7.5)
Ankylosing spondylitis 14 (6.4) 11 (6.1) 25 (6.9)
Nausea 11 (5.0) 12 (6.7) 23 (6.4)
Bronchitis 14 (6.4) 9 (5.0) 23 (6.4)
Nasopharyngitis 14 (6.4) 9 (5.0) 23 (6.4)
Leukopenia 8 (3.7) 14 (7.8) 22 (6.1)
Uveitis 13 (6.0) 9 (5.0) 21 (5.8)
Urinary tract infection 11 (5.0) 10 (5.6) 21 (5.8)
Hypertension 8 (3.7) 13 (7.3) 21 (5.8)
Gastroenteritis 9 (4.1) 10 (5.6) 19 (5.3)
Selected AEs of interest, n (exposure-adjusted incidence rate per 100 patient-years)
Serious infections 3 (0.5) 9 (1.5) 12 (1.0)
Candida infections 3 (0.5) 2 (0.3) 5 (0.4)
Crohn’s disease 2 (0.3) 5 (0.8) 7 (0.6)
Ulcerative colitis 1 (0.2) 1 (0 2) 2 (0.2)
MACE (adjudicated) 2 (0.3) 5 (0.8) 7 (0.6)
Malignant/unspecified tumours 4 (0.7) 2 (0.3) 6 (0.5)
Neutropenia 3 (0.5) 5 (0.8) 8 (0.7)
Uveitis 2.3 1.5 1.8
aIncludes patients originally randomized to secukinumab and those re-randomized from placebo to secukinumab at Wk16/24;
AE data in patients who up-titrated from secukinumab 75150 mg are attributed to their dose at the time of AE onset. bMean
(S.D.). cInclude deaths. dUp to Wk104; 2 additional patients discontinued secukinumab after Wk104. eIncludes one case of
new-onset latent tuberculosis infection and one case of primary pulmonary tuberculoma. fDetails reported previously [10, 12].
AEs: treatment-emergent adverse events; IV: intravenous; MACE: major adverse cardiac events; n, number of subjects who
received 51 dose of secukinumab at any time during the core trial or extension, including those randomized at baseline to
secukinumab or placebo; SAE: serious adverse event; TB: tuberculosis; Wk, week.
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progression in 80.6% of patients [24]. Furthermore, longitu-
dinal data from cohort studies suggest a longer duration of
anti-TNF therapy is required before a positive effect on
radiographic structural damage is observed [20, 25, 26]. In
these analyses, secukinumab 150 mg, the approved dose in
AS, demonstrated a sustained low mean change from base-
line in mSASSS through 4 years (i.e. 0.5 over 2 years and 1.2
over 4 years). Direct comparisons between the current struc-
tural progression results and those of previous studies
cannot be made because of differences in the study designs
and populations; however, comparative data will become
available from SURPASS, an ongoing 2-year randomized
and active-controlled head-to-head study comparing radio-
graphic structural progression with secukinumab vs an anti-
TNF agent in AS [27].
MRI analyses demonstrated that secukinumab reduced
objective signs of spinal inflammation in active AS, and
that these improvements were sustained through 208Wk
of therapy. These results were consistent with the reduc-
tion in hsCRP levels, another objective measure of inflam-
mation, seen over 4 years of secukinumab treatment.
Secukinumab showed a favourable safety profile
through 4 years, with similar EAIRs for selected AEs (e.g.
serious infections, Candida, Crohn’s disease, uveitis), as
previously reported [10, 12]. Uveitis is a common extra-
articular manifestation of spondyloarthritis with an esti-
mated prevalence of 33.2% in patients with AS. The
EAIRs of uveitis reported in AS patients treated with TNF
inhibitors are 2.63.5 per 100 patient-years [28, 29]. The
EAIR of uveitis in this study was 1.8 per 100 patient-years,
suggesting a low to comparable incidence of uveitis in
secukinumab-treated AS patients.
Furthermore, no new safety risks were identified during
this extended secukinumab treatment analysis.
Limitations of this 4-year extension study include the
lack of a control group beyond Wk16/24 and the potential
for selection bias among subjects choosing to enter the
extension study. However, the lower 75 mg dose has util-
ity as a randomized comparator arm of a less effective
dose that demonstrates numerical dose-separation on
multiple endpoints, including radiographic progression.
Although, the results of the present analysis show a
trend for numerically improved clinical efficacy and radio-
graphic outcomes with secukinumab 150 vs 75 mg, the
study was not powered for such a comparison.
The results of this ongoing 5-year study build on the
extension study findings previously reported from the
MEASURE 1 study at 3 years and confirm the sustained
efficacy and known safety profile of secukinumab through
Wk208 (4 years) [12].
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